TY - JOUR
T1 - Dapagliflozin (Forxiga) for type 2 diabetes?:
AU - Bailey, Clifford
PY - 2013/9/12
Y1 - 2013/9/12
N2 - In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.1 Aims of treatment include minimising long-term complications (e.g. cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding unwanted effects of treatment (e.g. severe hypoglycaemia, weight gain).2 Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.2 ▼Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.3 It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control.3 The company's advertising materials claim that dapagliflozin provides a “novel method of controlling excess glucose” with “secondary benefit of weight loss”. Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.
AB - In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.1 Aims of treatment include minimising long-term complications (e.g. cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding unwanted effects of treatment (e.g. severe hypoglycaemia, weight gain).2 Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.2 ▼Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.3 It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control.3 The company's advertising materials claim that dapagliflozin provides a “novel method of controlling excess glucose” with “secondary benefit of weight loss”. Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.
UR - https://dtb.highwire.org/lookup/doi/10.1136/dtb.2013.9.0205
U2 - 10.1136/dtb.2013.9.0205
DO - 10.1136/dtb.2013.9.0205
M3 - Article
C2 - 24030968
SN - 0012-6543
VL - 51
SP - 105
EP - 108
JO - Drug and Therapeutics Bulletin
JF - Drug and Therapeutics Bulletin
IS - 9
ER -